Please upgrade your browser.
KCA CEO, Bill Bro, a 24-year kidney cancer survivor, serves as a member of NCI’s Renal Cancer Task Force, as well as an adviser to the Kidney Cancer SPORE, a federally funded program of research excellence based in Boston.
Scientists have hailed the finding “unexpected and exciting”.
Legislation has been introduced in Springfield that would help open the door to a new generation of medicines that could help treat kidney cancer and other chronic, debilitating diseases.
During Kidney Cancer Awareness Month, the Kidney Cancer Association highlights some of the many effective collaborations it has formed with other cancer organizations.
The chance of contracting renal cell carcinoma, a common type of kidney cancer, can be reduced to a great extent by including cod fish in the diet.
Small kidney tumours have an agressive potential and should be treated, according to a the results of a large multicentre study presented at the 28th Annual EAU Congress in Milan.
IL-11 and its receptor, IL-11Ra, are expressed in human cancers; however, the functional role of IL-11 in tumor progression is not known. We found that IL11 is a hypoxia-inducible, VHL-regulated gene in human cancer cells and that expression of IL11 mRNA was dependent, at least in part, on HIF-1.
The annual report contains plenty of good news concerning funding for kidney cancer research projects.
The purpose of this study is to assess the safety and tolerability of BMS-986015 given in combination with BMS-936558...
Tivozanib is an oral inhibitor of vascular endothelial growth factor (VEGF), and inhibits all three VEGF receptors. AVEO Pharmaceuticals (AVEO) submitted an NDA in September 2012, based on results of the global Phase III TIVO-1 trial, a randomized superiority-designed pivotal trial evaluating the efficacy and safety of tivozanib compared to sorafenib (Nexavar®) in 517 patients with advanced renal cell carcinoma ((RCC)) who had no prior treatment with a systemic therapy, as well as data from 17 clinical studies involving over 1,000 subjects who received tivozanib.
|Powered by NeonCRM|